Avsnitt
-
The US Food and Drug Administration (FDA) issued new draft regulatory guidance for pulse oximeters related to skin pigment. The guidance is a step forward but it may have unintended consequences. Authors Michael Lipnick, MD, and Philip Bicker, MD, PhD, professors of anesthesia at University of California, San Francisco, discuss this and more with JAMA Executive Editor Gregory Curfman, MD.
Pulse Oximetry and Skin Pigmentation—New Guidance From the FDA Adherence to FDA Guidance on Pulse Oximetry Testing Among Diverse Individuals, 1996-2024 Addressing Racial and Ethnic Bias in Pulse Oximeters—A Wicked Problem Evaluating the Accuracy of Pulse Oximetry in Children According to Race
Related Content: -
The CAUGHT-CAD randomized clinical trial sought to determine whether a CAC score-informed strategy could slow the progression of coronary plaque volume. Author Thomas H. Marwick of the Baker Heart & Diabetes Institute joins JAMA Associate Editor Pradeep Natarajan to discuss "Effects of Combining Coronary Calcium Score With Treatment on Plaque Progression in Familial Coronary Artery Disease."
Effects of Combining Coronary Calcium Score With Treatment on Plaque Progression in Familial Coronary Artery Disease Cardiac CT Calcium Score Coronary Artery Calcium Testing—Too Early, Too Late, Too Often Filling the Evidence Gaps Toward a Coronary Artery Calcium-Guided Primary Prevention Strategy
Related Content: -
Saknas det avsnitt?
-
The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses results of the first 4 drug regimens from this platform trial and how this study design makes efficient use of resources, with JAMA Deputy Editor Christopher Muth, MD.
Platform Clinical Trials for the Efficient Evaluation of Multiple Treatments Pridopidine in Amyotrophic Lateral Sclerosis Platform Trials in ALS Verdiperstat in Amyotrophic Lateral Sclerosis Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis CNM-Au8 in Amyotrophic Lateral Sclerosis
Related Content: -
Understanding health conditions with the most spending and variation across locations and over time is important for identifying trends, inequalities, and strategies for lowering health spending. Joseph Dieleman, PhD, of the University of Washington speaks with JAMA Associate Editor Karen Joynt Maddox, MD, MPH, about county-level variation in health care spending across the US.
Tracking US Health Care Spending by Health Condition and County
Related Content: -
Two recent studies published in JAMA provide evidence about the effects of state-level abortion restrictions on birth rates and infant mortality. Author Alyssa Bilinski, PhD, MSc, of Brown University School of Public Health joins JAMA Deputy Editor Tracy Lieu, MD, to discuss her related Editorial "Abortion May Be Controversial—Supporting Children and Families Need Not Be."
Abortion May Be Controversial—Supporting Children and Families Need Not Be
Related Content: -
Contemporary models of dementia care are multidisciplinary and aim to bridge medical and social services. Julie P. W. Bynum, MD, MPH, of the University of Michigan speaks with JAMA Deputy Editor Christopher C. Muth, MD, about 2 trials—the D-CARE and IN-PEACE trials—that evaluated care models to support people diagnosed with dementia and their caregivers.
Challenges and Innovations in Dementia Care—Evaluating Comprehensive Models Health System, Community-Based, or Usual Dementia Care for Persons With Dementia and Caregivers Palliative Care Program for Community-Dwelling Individuals With Dementia and Caregivers
Related Content: -
Two new trials published in JAMA evaluate the efficacy of periprocedural intra-arterial thrombolytics after successful endovascular thrombectomy for patients with acute ischemic stroke. Diederik Dippel, MD, PhD, of Erasmus University Medical Center discusses this and more with JAMA Deputy Editor Christopher C. Muth, MD.
Intra-Arterial Thrombolytics During Thrombectomy for Ischemic Stroke—End of the Story or a New Beginning? Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke
Related Content: -
Private equity acquisitions of health care facilities have rapidly increased over the past decade. However, little is known about the effects of these acquisitions on patient experience. Author Rishi K. Wadhera, MD, MPP, MPhil, of Harvard Medical School discusses this topic with JAMA Associate Editor Karen Joynt Maddox, MD, MPH.
Changes in Patient Care Experience After Private Equity Acquisition of US Hospitals
Related Content: -
Certain CD4+ T-cell subtypes play a role in asthma. Characterizing asthma endotypes in diverse groups is important to help develop effective therapies for youth with asthma. Author Juan C. Celedon, MD, DrPH, University of Pittsburgh, Department of Pediatrics, discusses this and more with JAMA Deputy Editor Kristin L. Walter, MD, MS.
Transcriptomic Profiles in Nasal Epithelium and Asthma Endotypes in Youth
Related Content: -
Most Medicare Advantage (MA) plans offer dental care coverage as a supplemental benefit. However,few beneficiaries are enrolled in an MA plan that provides comprehensive dental benefits. Lisa Simon, MD, DMD, discusses this and more with JAMA Deputy Editor Kristin L. Walter, MD, MS.
Availability of Dental Benefits Within Medicare Advantage Plans by Enrollment and County
Related Content: -
Long COVID is now defined as a heterogeneous, infection-associated chronic condition present for at least 3 months after SARS-CoV-2 infection. Author Leora Horwitz, MD, MHS, of NYU Grossman School of Medicine joins JAMA Executive Editor Gregory Curfman, MD, to discuss the JAMA article "2024 Update of the RECOVER-Adult Long COVID Research Index."
2024 Update of the RECOVER-Adult Long COVID Research Index Characterizing Long COVID in Children and Adolescents
Related Content: -
Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients with Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial."
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
Related Content: -
New antiretroviral drugs and formulations continue to become available for the prevention and management of HIV infection. Author Rajesh T. Gandhi, MD, joins JAMA Deputy Editor Preeti Malani, MD, MSJ, to discuss these new approaches for HIV.
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel Advances in Treatment and Prevention of HIV
Related Content: -
A new JAMA study examines the association between severe maternal morbidity in a first birth and the probability of a subsequent birth. Authors Neda Razaz, PhD, and Eleni Tsamantioti, MD, MMedSc, both from the Karolinska Institute in Sweden, discuss this and more with JAMA Associate Editor Melissa A. Simon, MD, MPH.
Association of Severe Maternal Morbidity With Subsequent Birth Severe Maternal Morbidity and Subsequent Birth—Understanding and Informing a Woman’s Choice
Related Content: -
Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic’s Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration.
Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
Related Content: -
Preterm birth is the greatest cause of neonatal mortality and morbidity, with infants born extremely preterm at highest risk. Author Brett J. Manley, PhD, the Royal Women’s Hospital, Melbourne, Australia, discusses a new study of the effect of intratracheal corticosteroid administration on survival free of bronchopulmonary dysplasia in preterm infants, with JAMA Deputy Editor Tracy A. Lieu, MD, MPH.
Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants
Related Content: -
Preventing obesity in early childhood is challenging for clinicians and families. Authors Eliana M. Perrin, MD, MPH, of Johns Hopkins University, and William J. Heerman, MD, MPH, of Vanderbilt University, join JAMA Deputy Editor Tracy Lieu, MD, to discuss "A Digital Health Behavior Intervention to Prevent Childhood Obesity: The Greenlight Plus Randomized Clinical Trial."
A Digital Health Behavior Intervention to Prevent Childhood Obesity
Related Content: -
A new study published in JAMA found that drug-related supply chain issue reports were 40% less likely to result in meaningful drug shortages in Canada compared with the US. Authors Kate Suda, PharmD, MS, of University of Pittsburgh School of Medicine, and Mina Tadrous, PharmD, PhD, of University of Toronto, discuss this and more with JAMA Deputy Editor Joseph S. Ross, MD, MHS.
Differences in Drug Shortages in the US and Canada Understanding Drug Supply Shortages in the US and Canada
Related Content: -
In the US, childbirth typically occurs in hospitals or accredited birth centers. President of the American College of Obstetricians and Gynecologists Stella Marie Dantas, MD, speaks with JAMA Deputy Editor Linda Brubaker, MD, MS, about newly proposed advanced birth centers that would permit higher-risk births, with concerns for patient safety and rural obstetric care access.
Advanced Birth Centers and the Effect on Maternity Care
Related Content: -
The Declaration of Helsinki originated in 1964, developed by the World Medical Association (WMA). Process Chair Jack S. Resneck Jr, MD, discusses the 2024 updates to the Declaration of Helsinki with JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS.
Revisions to the Declaration of Helsinki on Its 60th Anniversary World Medical Association Declaration of Helsinki Making the Ethical Oversight of All Clinical Trials Fit for Purpose The Revised Declaration of Helsinki—Considerations for the Future of Artificial Intelligence in Health and Medical Research Revisiting the Declaration of Helsinki—A Patient-Centered Perspective Future-Proofing Research Ethics—Key Revisions of the Declaration of Helsinki 2024 The Revision of the Declaration of Helsinki Viewed From the Americas—Paving the Way to Better Research Declaration of Helsinki—Revisions for the 21st Century Facilitating Efficient and Ethical Trials at the Intersection of Research and Clinical Care The 2024 Revision to the Declaration of Helsinki
Related Content: - Visa fler
